Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2001

View Archived Issues

Flamel Technologies completes controlled-release antibiotic study

Amgen submits supplemental application with EMEA for anemia product

Genzyme General highlights Q3 developments

Catalytic antioxidant AEOL-10150 protects hamsters against radiation-induced mucositis

Combination of CCI-779 and 5-FU/LV associated with significant toxicity in phase I study

European Generx trial approved and set to commence

Impact of addition of BMS-275291 to paclitaxel/carboplatin examined in phase II/III trial in NSCLC

Merck KGaA and Forest to comarket treatment for alcohol addiction in the U.S.

Antimicrotubule agent T-900607 well tolerated in ongoing phase I trial in advanced cancer patients

Novel platinum analogue shows evidence of activity, adequate safety in phase II cancer trials

Tissue engineering product to begin clinical trials in the U.S.

SU-5416 may be useful in certain patients with c-kit-positive AML, according to phase II data

Gilead licenses its SELEX technology to Archemix

NXY-059 may have advantages over current neuroprotectants for the treatment of stroke

Merger of Barr and Duramed finalized this week

Oxigene regains rights to anticancer combretastatins, ends development of declopramide

Novartis receives approvable letter for Diovan as treatment for heart failure

ACG news: pilot study of APC-2059 demonstrates safety and activity in ulcerative colitis

Second activated macrophage therapy trial initiated in Belgium

Novel protein identified at CuraGen shows promise in IBD

Pyrimidines inhibit CDKs and FAK according to recent AstraZeneca patent

New series synthesized at Bayer shows inhibitory activity against cGMP-PDE

Takeda discloses agents for inflammation, arthritis and bone disorders

Scios patents discoveries in the field of bradykinin antagonists

New chroman derivatives designed at Akzo Nobel with affinity for estrogen receptors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...